Company intelligence / Profile preview

Neeman Medical International

Raleigh, North Carolina, United States

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Neeman Medical International is a global Contract Research Organization (CRO) that provides comprehensive clinical trial management services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1997, the company specialized in Phase II-IV clinical trials with a significant geographic footprint in emerging markets, particularly India and Latin America. Its service portfolio includes site selection, regulatory affairs, clinical monitoring, and data management. In 2015, Neeman Medical International was acquired by JSS Medical Research, a leading Canadian CRO, to enhance its global reach and service capabilities. The company is recognized for its expertise in navigating complex regulatory environments in diverse international regions.

Industry: Contract Research Organization

Beyond the preview

Go deeper on Neeman Medical International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neeman Medical International.

Explore the full profile